Cosmo pharmaceuticals


Cosmo is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. We develop and manufacture products which are distributed globally by our partners.

Our strategy

In gastroenterology our focus is to improve the safety profile and efficacy of molecules that are already on the market. 

In dermatology we aim to develop novel therapies which have minimal side-effects.

In healthtech we are developing cutting-edge intelligent medical devices to assist with clinical decision-making; our first device aids endoscopists in the detection of colonic mucosal lesions.

Our clinical focus

Cosmo is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. 

Products which Cosmo has developed include: Lialda®/ Mezavant®/Mesavancol® and Uceris®/Cortiment®, for the treatment of ulcerative colitis; GI Genius™, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview®, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo® for the treatment of travellers’ diarrhoea (‘TD’) and Winlevi® for the treatment of acne. 

Proprietary technology

The Company’s extensive galenic experience, which led to the development of the proprietary multi-matrix technology MMX®, provides an excellent basis for the development of new, patentable, yet lower-risk products, manufactured at the Company’s own current good manufacturing practices (‘cGMP’) approved plant. Cosmo has a demonstrated ability to successfully identify unmet medical needs, manage the drug development process and obtain regulatory approval for new products. Cosmo then licenses its approved products to partners with strong marketing and sales expertise.

Our target therapies

Cosmo’s therapeutic focus is on the oral and endoscopic treatment of colon diseases, primarily bowel diseases and colorectal cancer prevention. Our MMX® technology allows the delivery of active pharmaceutical ingredients into the lumen of the colon through tablets, in a delayed and controlled way, with the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.